Santhera Pharmaceuticals Holding (LSE:0QN1) - Aandelenkoers, Nieuws & Analyse

0QN1 Overzicht aandelen

0QN1 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	6/6
Prestaties in het verleden	3/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 98.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 35.4% per jaar groeien

Dit jaar winstgevend geworden

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Grote eenmalige posten die de financiële resultaten beïnvloeden

Aandeelhouders zijn het afgelopen jaar verwaterd

Santhera Pharmaceuticals Holding AG Concurrenten

Bioventix

AIM:BVXP

UK£197.0m

Genus

LSE:GNS

UK£1.1b

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Compugen

NasdaqCM:CGEN

US$144.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Santhera Pharmaceuticals Holding
Historische aandelenkoersen
Huidige aandelenkoers	CHF 8.32
52 Week Hoogtepunt	CHF 11.34
52 Week Laag	CHF 7.70
Bèta	0.13
11 maand verandering	-7.25%
3 maanden verandering	-8.07%
1 Jaar Verandering	-9.70%
33 jaar verandering	-35.53%
5 jaar verandering	-93.18%
Verandering sinds IPO	-78.39%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0QN1	GB Biotechs	GB Markt
7D	3.7%	2.5%	2.2%
1Y	-9.7%	-15.4%	9.0%

Rendement versus industrie: 0QN1 overtrof de UK Biotechs industrie, die het afgelopen jaar een rendement -15.4 % opleverde.

Rendement versus markt: 0QN1 presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 9 % opleverde.

Prijsvolatiliteit

Is 0QN1's price volatile compared to industry and market?
0QN1 volatility
0QN1 Average Weekly Movement	6.4%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0QN1 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van 0QN1 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	45	Dario Eklund	www.santhera.com

Santhera Pharmaceuticals Holding AG, een gespecialiseerd farmaceutisch bedrijf, ontwikkelt en commercialiseert samen met haar dochterondernemingen geneesmiddelen voor zeldzame neuromusculaire en longziekten met een grote onbeantwoorde medische behoefte in Europa, Noord-Amerika en Azië. De belangrijkste pijplijnkandidaat van het bedrijf omvat Vamorolone, dat wordt ontwikkeld voor de behandeling van Duchenne spierdystrofie (DMD). De pijplijn in klinische fase omvat ook Lonodelestat voor de behandeling van taaislijmziekte en andere neutrofiele longziekten.

Santhera Pharmaceuticals Holding AG Samenvatting

Hoe verhouden de winst en inkomsten van Santhera Pharmaceuticals Holding zich tot de beurswaarde?
0QN1 fundamentele statistieken
Marktkapitalisatie	CHF 100.12m
Inkomsten(TTM)	CHF 62.86m
Inkomsten(TTM)	CHF 113.59m

1.6x

Koers/Winstverhouding

0.9x

P/S-verhouding

Is 0QN1 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0QN1 resultatenrekening (TTM)
Inkomsten	CHF 113.59m
Kosten van inkomsten	CHF 6.52m
Brutowinst	CHF 107.07m
Overige uitgaven	CHF 44.21m
Inkomsten	CHF 62.86m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	5.19
Brutomarge	94.26%
Nettowinstmarge	55.34%
Schuld/Eigen Vermogen Verhouding	49.2%

Hoe presteerde 0QN1 op de lange termijn?

Bekijk historische prestaties en vergelijking

0QN1 Overzicht aandelen

Beloningen

Risicoanalyse

Santhera Pharmaceuticals Holding AG Concurrenten

AIM:BVXP

UK£197.0m

LSE:GNS

UK£1.1b

AIM:C4XD

UK£30.3m

NasdaqCM:CGEN

US$144.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Santhera Pharmaceuticals Announces Positive Topline Results from LIONHEART Study with AGAMREE®? (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

First half 2024 earnings released: CHF1.35 loss per share (vs CHF2.09 loss in 1H 2023)

Santhera Pharmaceuticals Holding AG to Report First Half, 2024 Results on Sep 12, 2024

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

New minor risk - Market cap size

Less than half of directors are independent

Recent updates

Santhera Pharmaceuticals Announces Positive Topline Results from LIONHEART Study with AGAMREE®? (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

First half 2024 earnings released: CHF1.35 loss per share (vs CHF2.09 loss in 1H 2023)

Santhera Pharmaceuticals Holding AG to Report First Half, 2024 Results on Sep 12, 2024

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

New minor risk - Market cap size

Less than half of directors are independent

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on May 31, 2024

Third quarter 2023 earnings released

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA

New minor risk - Financial data availability

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

New major risk - Financial position

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Santhera Pharmaceuticals Holding AG Launches AGAMREE (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Market cap size

First half 2023 earnings released: CHF2.09 loss per share (vs CHF5.24 loss in 1H 2022)

Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG (SWX:SANN).

Santhera Pharmaceuticals Holding AG to Report First Half, 2023 Results on Sep 07, 2023

Forecast breakeven date moved forward to 2023

Santhera Pharmaceuticals Holding AG announced that it expects to receive $14.999996 million in funding from Catalyst

Full year 2022 earnings released

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Santhera and Reveragen Announces FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

First half 2022 earnings released: CHF0.52 loss per share (vs CHF0.92 loss in 1H 2021)

European Medicines Agency Validates Santhera Pharmaceuticals Holding AG’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG to Report First Half, 2022 Results on Oct 31, 2022

Forecast to breakeven in 2024

Santhera Pharmaceuticals Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

Santhera Pharmaceuticals Holding AG and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Insufficient new directors

Santhera Pharmaceuticals Holding AG Announces Board Changes

Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone

Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Jun 29, 2022

Insufficient new directors

Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and a Member of Santhera’s Executive Management Team, Effective May 1, 2022

Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling New Drug Application Submission to U.S. Food and Drug Administration

Forecast to breakeven in 2024

Insufficient new directors

Forecast to breakeven in 2024

Insufficient new directors

Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in funding from Highbridge Capital Management, LLC

First half 2021 earnings released: CHF0.92 loss per share (vs CHF2.78 loss in 1H 2020)

Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 35 million in funding from Idorsia Pharmaceuticals Ltd., Highbridge Capital Management, LLC, Waypoint Capital and other investors

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

Executive VP, Chief Medical Officer & Head of Development has left the company